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ABSTRACT
BACE1 is the protease responsible for the produc-
tion of amyloid-b peptides that accumulate in the
brain of Alzheimer’s disease (AD) patients. BACE1
expression is regulated at the transcriptional, as
well as post-transcriptional level. Very high BACE1
mRNA levels have been observed in pancreas, but
the protein and activity were found mainly in brain.
An up-regulation of the protein has been described
in some AD patients without a change in transcript
levels. The features of BACE1 50 untranslated region
(50 UTR), such as the length, GC content, evolu-
tionary conservation and presence of upstream
AUGs (uAUGs), indicate an important regulatory
role of this 50 UTR in translational control. We
demonstrate that, in brain and pancreas, almost all
of the native BACE1 mRNA contains the full-length
50 UTR. RNA transfection and in vitro translation
show that translation is mainly inhibited by the
presence of the uAUGs. We provide a mutational
analysis that highlight the second uAUG as the main
inhibitory element while mutations of all four uAUGs
fully de-repress translation. Furthermore, we have
evidence that a sequence within the region 222-323
of the BACE1 50 UTR has a stimulatory effect on
translation that might depend on the presence of
trans-acting factors.
INTRODUCTION
BACE1 (b-site APP cleaving enzyme 1) is a type 1
membrane-associated aspartyl protease of 501 amino
acids (1–5). BACE1 is required for the processing of
neuregulin 1 type III, an EGF-like factor that activates
the EGF receptor in Schwann cells, thereby regulating the
myelination of axons in the peripheral and central
nervous system (6,7). In addition to neuregulin 1, other
BACE1 substrates have been identiﬁed, such as the
amyloid-b precursor-like proteins 1 and 2 (8,9), the ST6
b-galactosamide a-2,6-sialyltranferase 1 (10), the selectin
P ligand (11), the b subunits of voltage-gated sodium
channels (12) and the low-density lipoprotein receptor-
related protein 1 (13).
Historically, BACE1 has been discovered as the
secretase that cleaves the amyloid-b precursor protein
(APP) at the b-site. In order to generate the amyloid-b
peptide (Ab), APP has to be cleaved sequentially by
BACE1 (14–16) and the g-secretase complex (17,18) at the
b- and the g-site, respectively. Ab is the major component
of the senile plaques, the histological hallmark of
Alzheimer’s disease (AD) and its progressive accumula-
tion has been causally linked to neuronal impairment and
neurodegeneration (19,20).
BACE1 shows a tissue-speciﬁc expression pattern
(3,4,21). Post-transcriptional mechanisms must also play
an important role as shown by the lack of correlation
between mRNA and protein levels (2,3,22–24). Moreover,
it has been shown that BACE1 protein expression was up-
regulated in the brain of some sporadic AD patients
without changes in the level of the corresponding mRNA
(25–28), thereby suggesting that these mechanisms can
play a pathogenic role.
In addition to transcription, regulation of gene expres-
sion can be achieved by mRNA processing, transport,
localization and stability. Translation of mRNA can also
be regulated typically by sequences within the untrans-
lated regions (UTRs) and/or by interactions between the
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proteins or micro RNAs (miRNAs) (29). These interac-
tions are usually inhibitory and often interfere with the
initiation step of translation (30).
Protein translation in eukaryotes is predominantly
initiated by a cap-dependent scanning mechanism in
which the small ribosomal subunits, with the associated
translational initiation factors, are recruited to the 50 cap
structure and scan in a 50–30 orientation until the ﬁrst
AUG is recognized. Then, the large ribosomal subunit
joins the complex to initiate the protein synthesis (31).
In eukaryotes, recognition of an AUG as a translation
start codon critically depends on its surrounding sequence.
For mammals, the consensus sequence GCCA/
GCCAUGG provides an optimal context for initiation
(32), with the purine at position  3 and the G at position
þ4 being the most important nucleotides. The rate of
initiation is strongly inﬂuenced by the primary and
secondary structure of mRNAs. Two mechanisms for
escaping the ﬁrst-AUG rule, i.e. context-dependent leaky
scanning and re-initiation, enable downstream AUG
codons to be accessed in some mRNAs via scanning
(33). Leaky scanning is the process in which a small
ribosomal subunit can bypass an upstream AUG (uAUG)
in a poor context and reach a downstream AUG codon
that is in stronger context for translational initiation.
Re-initiation of translation occurs when, after translation
of an uORF, the small ribosomal subunit is not released
from the mRNA but resumes scanning. Having
re-acquired the necessary translational initiation factors,
it can re-initiate translation at a downstream AUG.
There are also some reports pointing towards a rare
viral mechanism, known as ribosome shunting, in
which the small ribosomal subunit binds the mRNA in
50 cap-dependent manner and scans downstream until it
reaches a stable RNA secondary structure, which is
bypassed due to shunting to a downstream-landing site
where the scanning is continued till the start AUG codon
is reached (34). Another way to initiate translation implies
a cap-independent mechanism that requires an internal
ribosome entry site (IRES) and has been extensively
described for some viral transcripts and a few cellular
transcripts (35–37).
Genes for potent regulatory proteins, such as cytokines,
growth factors, kinases, transcription factors, etc., often
produce mRNAs in which the 50 UTR is GC rich and/or
burdened by uAUG codons. The idea that these encum-
bered sequences are nature’s way of limiting the synthesis
of proteins that would be harmful if overproduced, is
supported by experimental data (31).
The 50 UTR of BACE1 mRNA is long, evolutionally
conserved, has a high GC content and four uAUGs, all
features that suggest the potential of translational regula-
tion. Indeed, two recent studies have demonstrated that
BACE1 50 UTR is inhibitory to translation (38,39).
However, they diﬀer in the interpretation of the data,
with one report (38) favoring a major role of uAUGs,
while the other (39) suggests that the GC-rich region of the
50 UTR forms a translation barrier that prevents the
ribosome from eﬃciently translating the BACE1 mRNA.
In addition, a third article (40) suggests that a shunting
mechanism can overcome the translational inhibition by
BACE1 50 UTR in a cell-speciﬁc manner. Therefore, the
mechanism of down-regulation of translation driven by
BACE1 50 UTR remains controversial.
In this study, we analyzed the mechanism of inhibition
of translation of BACE1 transcript by dissecting and
mutating its 50 UTR. We employed RNA transfection to
avoid possible artifacts arising from transcriptional or
splicing eﬀects that might occur with DNA transfection.
RNA transfection experiments were also compared with
in vitro translation assays to highlight the possible
contribution of trans-acting factors. By this approach,
we demonstrate that the translational control of BACE1
expression is mainly limited by the presence of uAUGs
rather than a major contribution from structural
determinants.
MATERIALS AND METHODS
Cell culture
Reagents and media for cell culture were provided from
Cambrex, East Rutherford, NJ, USA. HeLa cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 5% FCIII and 10% donor
horse serum, 100U/ml penicillin, 100mg/ml streptomycin
and 2mM glutamine. The cells were cultured at 378Ci na
humidiﬁed 5% CO2 atmosphere.
Plasmids
Plasmids pT3A-B1, pT3A-B1-1-218, pT3A-B1-222-323,
pT3A-B1-222-455, pT3A-B1-323-455 and pT3A-B1-395-
455 were generated by PCR ampliﬁcation of pZac-B1x-
Lucþ (38) with the following oligonucleotides (Sigma
Genosys, St. Louis, MO, USA): taa agg tac cag ctg cga gcc
(sense) and aat act cga gtg ggc ccc ggc ctt cgc (antisense)
for B1; taa agg tac cag ctg cga gcc (sense) and aat act cga
gta cat cgg cac ggc ggc ggc (antisense) for 1-218; taa agg
tac cgc ggg ctc cgg atc cca gc (sense) and aat act cga ggc
agg gcc ctg ggc cag c (antisense) for 222-323; taa agg tac
cgc ggg ctc cgg atc cca gc (sense) and aat act cga gtg ggc
ccc ggc ctt cgc (antisense) for 222-455; taa agg tac cag gcc
ctg gcg tcc tga tg (sense) and aat act cga gtg ggc ccc ggc ctt
cgc (antisense) for 323-455; taa agg tac cag gcg cca ggg acg
gac gt (sense) and aat act cga gtg ggc ccc ggc ctt cgc
(antisense) for 395-455. Ampliﬁed fragments were inserted
into pT3A (41) with KpnI-XhoI digestion and veriﬁed by
DNA sequencing. To generate the plasmid pT3A-B1-
i222-323, pT3A-B1 was digested with BamHI and PstI,
blunted with T4 DNA polymerase and re-ligated.
The same blunted backbone was used to prepare the
plasmid T3A-B1-222-323AS by antisense insertion of the
fragments 222-323 ampliﬁed by PCR.
pT3A-B1-mut2, pT3A-B1-mut1,2 and pT3A-B1-
mut1,2,3 were obtained by PCR ampliﬁcation of plasmids
pBRm2L-B1x-mut1, pBRm2L-B1x-mut2 and pBRm2L-
B1x-mut3 (38) with the same oligonucleotides described
above.
The last uAUG was mutated into UUG by PCR
performed with a sense oligo bearing the mutation (ggc cct
gca ggc cct ggc gtc ctg ttg ccc) and the antisense oligo used
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cleaved PstI-XhoI and inserted into plasmids pT3A-B1,
pT3A-B1-mut1,2,3 and pT3A-B1-mut2 in order to
generate pT3A-B1-mut4, pT3A-B1-mut1,2,3,4 (pT3A-
B1-mut #4) and pT3A-B1-mut2,4 respectively. pT3A-B1-
mut #4 222-323 plasmid was obtained by deletion of the
BamHI-PstI fragment from pT3A-B1-mut #4.
The plasmid sl200MLA.1 (42) was kindly provided
by Dr Thoma. sl200MLA.1 was digested EcoRV-SphI,
blunted and re-closed to obtain the empty vector
sl200LA.1. For preparing sl200LA.1-B1-222-323, the
vector pT3A-B1-222-323 was cleaved with KpnI, blunted
with T4 DNA polymerase and digested with SphI. The
fragments 222-323 obtained in this way was inserted into
EcoRV-SphI-cleaved sl200MLA.1.
To obtain the plasmid pTOPO-hBACE1, RT-PCR was
performed with total RNA from human brain (Clontech,
Palo Alto, CA, USA, lot number 5120091). Reverse
transcription was performed with Superscript II kit
(Invitrogen, Carlsbad, CA, USA). PCR was performed
with oligonucleotides agg agc ccg gag ccc ttg (sense) and
gct cct cgg gct ctt cgt c (antisense). Ampliﬁed fragments
were cloned in pTOPO vector (Invitrogen) according to
the manufacturer’s instructions.
In vitro transcription
Capped mRNAs were transcribed from 2mg of linearized
plasmid DNA in a 25ml reaction containing 1mM ATP,
1mM CTP, 1mM UTP, 10mM DTT, 52 U RNAsin
(Promega, Madison, WI, USA), 8.8mM m
7GpppG, 30 U
T3 or T7 polymerase (Promega) and 1  transcription
buﬀer (supplied with the RNA polymerase). After 10min
at 378C, 2mM GTP was added and the incubation
continued for additional 60min before treatment with 1U
RQ1 RNase-free DNase (Promega) for 15min at 378C.
RNA was extracted with phenol–chloroform–isoamylal-
cohol (25:24:1), precipitated with 2.5 volumes of ethanol
and 1/10 volumes of 3M sodium acetate (pH 5.2),
recovered by centrifugation, washed with 75% ethanol
and dissolved in deionized water.
RNA transfection
For RNA transfection, TransMessenger Transfection
Reagent (Qiagen, Valencia, CA, USA) was used according
to the manufacturer’s instructions. The ratio between
Renilla and ﬁreﬂy reporters was 1:4. The transfection
reagent was substituted with MEM after 3h, and the
luminescence was measured after 24h. All in vitro-
transcribed mRNAs used in transfection experiments
contained 50 end cap structure and poly(A) tail.
In vitro translation
In vitro translation was performed in HeLa cell extracts
(43). The assays were performed in a volume of 10ml with
0.07pmol of the mRNA of interest and 0.026pmol of
the control Renilla reporter mRNA. Standard reactions
contained 40% (v/v) HeLa extract, 60mM amino
acids, 20mM creatine phosphate, 0.04mg/ml creatine
kinase, 16mM HEPES pH 7.6, 0.8mM ATP, 0.1mM
GTP, 50mM spermidine, 0.6U RNase inhibitor
(Eppendorf, Hamburg, Germany), 2.5mM magnesium
acetate and 40mM potassium acetate. The reactions were
incubated at 378C for 30min and stopped by snap freezing
in liquid nitrogen.
RNase protection
BACE1 riboprobes were prepared starting from XbaI-
linearized pTOPO-hBACE1 in 20ml reactions with 12mM
cold CTP and 50mCi [a-
32P] CTP per reaction.
Transcription was driven by Sp6 polymerase at 428C
for 1h, followed by 15min DNA digestion by 1U RQ1
RNase-free DNase (Promega). Hot riboprobes were
extracted with phenol–chloroform–isoamylalcohol
(25:24:1) and passed twice over CHROM SPIN
100 columns (BD Bioscience, Palo Alto, CA, USA). The
RNase protection was performed with RPA III (Ambion,
Austin, TX, USA) according to the instruction manual.
Yield and speciﬁc activity were calculated for every probe.
In particular, 3–10-fold molar excess of probe was added
into the reaction, as recommended, to avoid problems
with saturation. The hybridization was overnight at 608C
and RNase digestion was performed with 1:100 dilution of
RNase A/T1 mix. Every experiment contained the
undigested probe and a yeast-RNA preparation as
negative control. A [g-
32P]-ATP labeled 50bp DNA
ladder (New England Biolabs, Beverly, MA, USA) was
used as a size reference on the gel.
Real-time PCRanalysis
Here,  2mg of total RNA was used for ﬁrst strand
cDNAs synthesis with random primers and Superscript
II reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions. Quantitative real-time
RT-PCR was performed using SYBR green and an ABI
7500 sequence detection system instrument and software
(Applied Biosystems, Foster City, CA, USA). Stability
assays were performed in duplicates from two independent
tissue culture or in vitro translation experiments. The
ﬁreﬂy luciferase values obtained in stability assays
were normalized to Renilla luciferase mRNA levels.
Analysis of endogenous BACE1 mRNA from human
brain and pancreas were performed with samples from
Clontech (lot number 5120091 and 5090033, respec-
tively). Values of endogenous BACE1 mRNA levels
were normalized to the mRNA levels of the ribosomal
protein L19. Primers used for detection of endogenous
BACE1 mRNA levels were: hqPCR1657f (tgg agg gct
tct acg ttg tct t) and hqPCR1742r (cct gaa ctc atc gtg
cac atg).
RESULTS
Since in a previous study (38) we suggested the presence of
alternatively spliced variants of the 50 UTR of BACE1
mRNA, we performed RNase protection assays using
total RNA isolated from human brain and pancreas
before starting a molecular characterization of the 50
UTR. The riboprobe was designed to protect most of the
transcript leader and 166nt of the main open reading
frame (ORF) (Figure 1A). The full-length BACE1 50 UTR
Nucleic Acids Research, 2007, Vol. 35, No. 9 2977was expected to protect a fragment of 536nt, while the
putative alternatively spliced variant was expected to
protect a fragment of 403nt. Total RNA from human
brain and pancreas was ﬁrst loaded on an agarose gel to
conﬁrm that both RNA preparations are of comparable
quality (Figure 1B). These RNAs were incubated with the
BACE1
32P-labeled riboprobe alone or with a mixture
containing the BACE1 riboprobe and a GAPDH ribop-
robe. An estimated 3–10 molar excess of the probe was
used to avoid saturation and the higher signal from
GADPH riboprobe in brain was considered an internal
control of the procedure. In all reactions, only the band
corresponding to the BACE1 full-length 50 UTR was
detected, questioning the existence of diﬀerent BACE1
transcript leaders under normal physiological conditions
(Figure 1C). Interestingly, the intensity of the signal
protected by the BACE1 riboprobe was comparable in
both tissues and quantitative RT-PCR conﬁrmed that
BACE1 mRNA is expressed in both tissues almost at the
same level (Figure 1D). This ﬁnding contradicts earlier
ﬁndings in which BACE1 mRNA expression in human
pancreas was reported to be much higher than in human
brain (3,4,39).
Ruling out an alternative splicing event in the transcript
leader, we moved toward the mechanism of translational
regulation of BACE1 by performing a detailed deletion
and mutation analysis of its 50 UTR. Since it was
previously reported that some regions of the BACE1
50 UTR might have promoter activity (44,45), we
employed a RNA transfection assay and in vitro transla-
tion analysis, techniques that allow exclusively monitoring
of translation, hence avoiding putative transcriptional/
post-transcriptional eﬀects such as cryptic promoter
activity and RNA splicing.
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Figure 1. BACE1 mRNA in human brain and pancreas contains the full-length 50 UTR. (A) Schematic representation of the riboprobe. The
riboprobe was designed to protect most of the transcript leader and 166nt of the ORF. A full-length BACE1 50 UTR was expected to protect a
fragment of 536nt (from 85 to 621), while the putative alternatively spliced variant was expected to protect a fragment of 403nt (from 218 to 621).
Arrows represent uAUGs, while black boxes represent uORFs. (B) Total RNAs from human brain (Br) and pancreas (Pan) have similar quality.
Equal amounts of total RNAs were separate on agarose gel. (C) RNase protection assay. 10mg of total RNA either from human brain or pancreas
were incubated with
32P-labeled riboprobe for BACE1 alone, or BACE1 and GAPDH together. Protected signal for BACE1 ( 500bp) and GAPDH
( 240bp) are indicated with arrows. Cont RNA¼control reaction without RNA, Br¼human brain, Pan¼human pancreas,
contþRNA¼control reaction with yeast RNA, ladder is g-ATP labeled 50bp DNA marker. (D) qPCR analysis. The values were normalized on
L19 expression (L19 ratio brain/pancreas¼0.6).
2978 Nucleic Acids Research, 2007, Vol. 35, No. 9To identify regions of the BACE1 50 UTR involved
in translational regulation, we generated the deletion
variants described in Figure 2A. These constructs were
used to prepare in vitro-transcribed reporter mRNAs with
the ﬁreﬂy luciferase ORF, containing a 50 m
7GpppG cap
structure and a poly(A) tail of 98 A-residues. Fireﬂy
mRNAs together with a Renilla luciferase control reporter
mRNA were used either in RNA-transfection experiments
in HeLa cells or in an in vitro translation assay based on
HeLa cell extracts. Deletion mutants showed a similar
trend in both systems, although the eﬀect on translation
was more pronounced in vivo (compare Figure 2B and C).
The 50-half of the sequence (1-218) bearing three out of
four uAUGs manifests a clear translational repression
that is even stronger in vivo (compare T3A-B1 and 1-218
in Figure 2B and C). This enhanced repression might
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Figure 2. Diﬀerent regions of BACE1 50 UTR aﬀect translation in a positive or negative manner. (A) Schematic representation of mRNAs bearing
diﬀerent BACE1 50 UTR deletion mutants and ﬁreﬂy luciferase as reporter gene. Black boxes represent uORFs, and arrows uAUGs. (B) RNA
transfections of diﬀerent deletion mutants in HeLa cell line together with Renilla control reporter mRNA. The results are presented in fold variation.
Error bars denote the standard deviation from the mean of at least three independent experiments. The star indicates a P50.05. (C) HeLa cell
extracts were co-programmed with ﬁreﬂy reporter mRNAs and Renilla reporter mRNA, used to account for diﬀerences in translatability of HeLa
extracts. (D and E) Reporter mRNAs stability is not aﬀected either in vivo or in vitro. Total RNA, isolated from RNA-transfected cells (B) and
in vitro translation reactions (C) at the beginning and end of experiment (upon 24h for RNA transfections or 30min for in vitro translations,
respectively) was transcribed into cDNA and ampliﬁed by qPCR with speciﬁc primers for the reporter genes. Rate of decay was calculated for each
reporter mRNA and the values were normalized to the control.
Nucleic Acids Research, 2007, Vol. 35, No. 9 2979be ascribed to the fact that this construct lacks the
putative stop codon of the uORF that originates from the
second uAUG. This creates an out-of-frame overlap of
that uORF with the main ORF, thereby enhancing the
possibility that the ribosomal scanning misses the start
codon of the reporter gene. Surprisingly, the 30-half of the
sequence (222-455) did not show any repression (compare
T3A-B1 and 222-455 in Figure 2B and C). Since it has
been previously reported that the 30-half of the BACE1 50
UTR might have strong inhibitory eﬀect via highly
structured regions (39), we performed a more detailed
deletion analysis of this region by generating constructs
323-455 and 395-455 (Figure 2A). Interestingly, the
reporter mRNA-bearing region 323-455 showed again an
inhibitory eﬀect that was more evident in vitro when
compared with the full-length reporter, while the 395-455
reporters did not show any signiﬁcant inhibitory eﬀect as
expected (Figure 2B and C, compare T3A-B1 with 323-455
and 395-455). These eﬀects on translational eﬃciency
could not be explained by diﬀerences in mRNA stability,
since qPCR analysis shows that the transcripts are equally
stable under given conditions (Figure 2D and E). The
in vivo analysis of deletion mutants reveals that the
BACE1 50 UTR represses translation by sequence
elements that are mainly present in the ﬁrst half of the
sequence. Interestingly, in addition to those regulatory
elements, the deletion analysis revealed a possible presence
of a translational activator: the comparison of translation
eﬃciency of reporter mRNAs bearing the region 222-455
and 323-455 suggests a possible positive eﬀect on
translation by the intermediate region 222-323.
To address the function of uAUGs in translational
regulation by BACE1 50 UTR in more detail, we
performed a mutational analysis (Figure 3A). According
to Kozak’s model (31), the ﬁrst uAUG in BACE1 50 UTR
is in an optimal context for translational initiation, since it
contains a purine at position  3, and a G at position þ4;
however, an U at position þ5 can reduce this optimal
context (46–48). The third and fourth uAUGs contain
pyrimidines at both positions  3 and þ4 and therefore are
not likely to be in an optimal context for eﬃcient
translation initiation. The context of the second uAUG
has a G at position  3, and a pyrimidine at position þ4,
thus, it is in a good, but not optimal context for
translation initiation.
Based on this prediction and on the results from the
deletion analysis, we started the evaluation of the uAUGs
by mutating the second uAUG into UUG (Figure 3A).
Translation of this reporter in vivo and in vitro gave
surprising results since this mutation (mut 2) diminished
translational repression from  14 to  2-fold in vivo, and
it was enough to completely bypass translational repres-
sion in vitro (Figure 3B and C, compare T3A-B1 and
mut 2), suggesting that the second uAUG indeed is
eﬃciently recognized. Additional mutation of the ﬁrst and
the third uAUG increased further translational eﬃciency,
but at least in vivo, the increase was very modest when
compared with the eﬀect of the mutation of the second
uAUG alone (Figure 3B and C, compare T3A-B1 with
mut 2, mut 1,2 and mut 1,2,3). The role of the fourth
uAUG was intriguing, since the deletion mutant that
starts in its close proximity (323-455) showed a lower
translational eﬃciency than the reporter mRNAs bearing
the putative positive regulatory element (i.e. 222-455),
suggesting that this uAUG may contribute to the transla-
tional repression. However, mutation of this uAUG alone
did not have any signiﬁcant impact on translational
eﬃciency in vivo and in vitro (Figure 3B and C, compare
T3A-B1 and mut 4). Nonetheless, mutation of the fourth
uAUG in addition to the second uAUG increased
additionally translational eﬃciency compared with the
eﬀect of the mutated second uAUG alone (Figure 3B and
C, compare mut 2 with mut 2,4).
When we mutated all four uAUGs, the translational
eﬃciency was 2–4-fold higher than control, in vivo and
in vitro (Figure 3B and C, see mut #4), in spite of the fact
that the BACE1 50 UTR has a very high GC content and a
strong predicted secondary structure (39).
We hypothesized that the good translatability of the
BACE1 50 UTR without uAUGs could be due to the
presence of the positive regulatory element in the region
222-323. This region could play a role in re-initiation
eﬃciency by acting as a spacer between the end of the
translation of the uORF and the beginning of the main
ORF and/or because of the sequence that surround the
stop codon of the uORF. Therefore, we evaluated the role
of the region 222-323 in translational regulation in the
context of both the wild-type BACE1 50 UTR, in order to
appreciate its eﬀect on re-initiation, and the 50 UTR
without uAUGs. We generated a number of additional
mutants (Figure 4A), which were used in both experi-
mental systems, in vivo and in vitro. The translational
eﬃciency driven by the region 222-323 alone was  3-fold
higher when compared to the control mRNA (Figure 4B
and C, see 222-323). This eﬀect was also analyzed in the
context of the full-length BACE1 50 UTR. In RNA-
transfection experiments, deletion of the 222-323 region
led to an additional decrease in translational eﬃciency
( 4-fold when compared with the wild-type sequence)
down to  60-fold below control (Figure 4B, see 222-323
and compare with T3A-B1). Replacement in antisense
orientation led to further decrease of translation eﬃciency
(Figure 4B, see 222-323as), showing that also the primary
sequence plays an important role. Interestingly, deletion
or antisense orientation of the region 222-323 in the
context of full-length BACE1 50 UTR did not inﬂuence
translation of the reporter gene in experiments performed
in vitro (Figure 4C).
To see whether the positive eﬀect of the region 222-323
in vivo is uAUG dependent, we deleted this region from
the construct in which all of the four uAUGs were
mutated (Figure 4A, mut #4 222-323). Deletion of this
region revealed a decrease in translational eﬃciency,
(3-fold in vivo and 2-fold in vitro), indicating that the
positive eﬀect of the region 222-323 on translation is, at
least partially, uAUG independent (Figure 4D, compare
mut #4 with mut #4 222-323, both in vivo and in vitro),
i.e. not only due to the positive eﬀect that this sequence
may exert on re-initiation eﬃciency. Although the
decrease in translation might look similar in the two
conditions (4-fold when uAUGs are present and 3-fold
when absent), it would be diﬃcult to compare those values
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Figure 3. uAUGs are responsible for low translational eﬃciency driven by BACE1 50 UTR. (A) Schematic representation of reporter mRNAs
bearing mutations of uAUGs. Arrows represent uAUGs or UUGs when mutated; black boxes symbolize uORFs. (B) Transfection of reporter
mRNAs into HeLa cell line. Renilla mRNA was used to normalize for transfection eﬃciency. Results are presented in fold variation, and the error
bars present the mean of at least three independent experiments. Star indicates a P50.05 (C) HeLa cell extracts were programmed with reporter
mRNAs as in (B). The data are normalized and presented in the same manner as in (B).
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Figure 4. Eﬀect of the 222-323 region of BACE1 50 UTR to translation. (A) Schematic representation of used reporter mRNAs. Arrows represent
uAUGs or UUGs when mutated; black boxes symbolize uORFs; dashed lines delimit deleted sequences; AS––antisense orientation. (B) The region
222-323 aﬀects strongly translation of wild-type BACE1 50 UTR in vivo. Transfection of reporter mRNAs into HeLa cell line. Renilla mRNA was
used to normalize for transfection eﬃciency. Results are presented in fold variation, and the error bars present the mean of at least three independent
experiments. (C) The region 222-323 does not aﬀect translation of wild-type BACE1 50 UTR in vitro. Renilla mRNA was used to normalize
diﬀerences in translatability of diﬀerent HeLa extract aliquots. Results are presented in fold variation, and the error bars present the mean of at least
three independent experiments. (D) The stimulatory eﬀect of the region 222-323 is uAUG independent in vivo and in vitro. Black bars represent RNA
transfection and white bars are in vitro translation experiments. Renilla mRNA was used to normalize for transfection eﬃciency and translatability of
diﬀerent HeLa extract aliquots. Results are presented in fold variation, and the error bars present the mean of at least three independent experiments.
(E) The region 222-323 does not act as IRES in vitro, in HeLa cell extract. Schematic representation of the IRES-containing reporter mRNAs is
shown above the graph. HeLa cell extracts were programmed with ApppG-capped c-myc (sl200MLA.1) or BACE1-222-323 reporter mRNAs bearing
a stabile hairpin upstream of a spacer sequence and the IRES (sl200A.1-B1-222-323). A reporter mRNA lacking an IRES element upstream of the
ﬁreﬂy luciferase ORF (sl200LA.1) was used as a control. Results are presented as percentage of translation. Error bars denote the standard deviation
from mean of at least three independent experiments.
2982 Nucleic Acids Research, 2007, Vol. 35, No. 9due to the diﬀerent translation eﬃciency of the corre-
sponding controls (T3A-B1 in Figure 4B and mut #4
in Figure 4D). Therefore, further investigation is
needed to assess the precise extent of uAUG-dependent
and -independent eﬀects. One possible explanation for the
uAUG-independent positive eﬀect of this region could
be that it can act as an IRES. However, the IRES
activity within this region was undetectable (Figure 4E).
Furthermore, we wanted to test if there is a speciﬁc
interaction between RNA-binding protein(s) and the
region 222-323 in an electro-mobility shift assay. Under
the standard experimental conditions we applied, we could
not detect speciﬁc interactions, possibly due to the high
GC content of BACE1 50 UTR (data not shown). Further
testing is required to evaluate the presence of any trans-
acting factor able to bind this region.
DISCUSSION
We have previously demonstrated that BACE1 translation
is inhibited by uAUGs in its 50 UTR (38). Other studies
suggested diﬀerent mechanisms involving inhibition by
highly structured regions (39) and the possibility to bypass
inhibitory regions in a cell-speciﬁc way by ribosomal
shunting (40). To shed more light on the molecular
mechanism of translational regulation of BACE1, we
performed a detailed analysis of its 50 UTR.
We have previously reported an alternative splicing
within BACE1 50 UTR (38). Since spliced forms of the 50
UTR of mRNAs have been reported to control protein
translation (31), we re-evaluated our ﬁndings. However,
the data obtained in this study question the existence of
BACE1 50 UTRs diﬀerent from the full-length form under
normal physiological conditions.
In the previous report, we used the MVA-T7pol
vaccinia virus expression system, a strategy that allows
the transcription of gene of interest to occur solely in the
cytosol (49). In spite of this, the robust transcription and
translation in cytosol driven by the virus can override the
physiological mechanisms of translational regulation. For
this reason, we preferred to use RNA transfection and
in vitro translation assay in this study, i.e. techniques that
mimic better the physiological conditions and should, in
principle, allow us to monitor exclusively translational
regulation and avoiding the interference of transcriptional
or additional post-transcriptional events.
The BACE1 50 UTR has a GC content of 77% and it is
predicted to form very strong secondary structures (39).
Secondary structures can play an important role in
translational regulation. A hairpin structure with a free
energy 5 30kcal/mol situated close to the cap structure
can impede scanning by interfering with the binding of the
small ribosomal subunit complex to the mRNA (50), while
a hairpin with a free energy 5 50kcal/mol can inhibit
scanning of the small ribosomal subunit (50–52). In the
case of BACE1, our results clearly imply that the high GC
content of BACE1 50 UTR, predicted to represent a
constitutive translational barrier, does not hinder the
scanning process of the small ribosomal subunit complex
as previously suggested (39). Instead, our data suggest that
uAUGs fully account for the observed inhibition of
BACE1 translation. It is noteworthy that we mutated
uAUGs into UUGs, i.e. we changed a purine with a
pyrimidine. Even though this kind of substitution might
produce subtle structural changes in the transcript, it is
unlikely that such mutations (as in case of the second
uAUG) would abolish a very strong secondary structure
that does not allow the small ribosomal subunit to go
through. Indeed, bioinformatic tools (such as MFOLD)
did not predict any signiﬁcant structural change upon
these substitutions.
The progressive rescue of BACE1 translation by
cumulative uAUG mutations also questions a possible
shunting mechanism in which the small ribosomal
complex could bypass inhibitory segments of the 50
UTR. In our analysis, instead, the contribution of all
uAUGs to translational eﬃciency, with the strongest
impact of the second uAUG, is more consistent with the
scanning model of translational initiation. The possibility
that shunting might aﬀect BACE1 levels in pathological
conditions is certainly intriguing, but it would require
further investigation.
The presence of uAUGs is usually inhibitory to
translation of the main ORF. uORFs can regulate
mRNA stability and translational eﬃciency in diﬀerent
ways (53). Our stability assay on deletion-containing
mRNA reporters suggests that the 50 UTR of BACE1 does
not aﬀect translation eﬃciency by changes in stability of
the mRNA. More notably, the mutational analysis of
uAUGs shows that all four uAUGs aﬀect translation, but
to a diﬀerent extent, being the second uAUG eﬃciently
recognized, while the others probably skipped by leaky
scanning. Interestingly, to make the construct 1-218, we
deleted the last nucleotide in the stop codon of the second
uORF, thereby we created an out of frame, overlapping
uORF. Eﬃcient recognition of the second uAUG (or even
the third in-frame uAUG) and translation of one of these
newly created overlapping uORF(s) could explain the
observed low translational eﬃciency of this reporter
mRNA in vivo. The rescue due to mutation of the
second uAUG revealed that it is eﬃciently recognized,
and the low-translational eﬃciency of construct 1-218,
indeed, could be ascribed to the translation of the newly
created overlapping uORF. Taking together these results,
we propose that BACE1 translation is mainly limited by
the low re-initiation frequency after translation of the
second uORF, while leaky scanning of the other uAUGs
seems rather eﬃcient and does not give a major contribu-
tion to the translational inhibition of BACE1. These data
on the key role of the second uAUG are consistent with a
recent report on the same subject (45), while the diﬀerent
results obtained by other groups (39,40) might be
explained by taking into account that the high GC content
of the BACE1 50 UTR hides a cryptic promoter activity
(38) that, albeit weak, might inﬂuence results in certain
conditions or in speciﬁc cell types.
For the process of re-initiation, the length and the
nucleotide sequence between the termination codon of
the translated uORF and the downstream initiation site
can be critical (54,55). Re-initiation can be inﬂuenced by
the nucleotide sequence around the termination codon,
Nucleic Acids Research, 2007, Vol. 35, No. 9 2983up to 12nt downstream. The decrease in translational
eﬃciency observed upon deletion of the 222-323 region
might indicate the importance of this region as a spacer
between the translated uORF and the downstream AUG.
On the other hand, the construct with the 222-323 region
in antisense orientation showed an even stronger transla-
tional repression suggesting that the primary sequence of
this region play a more important role than just as spacer
for the process of re-initiation, i.e. it could function as
positive element by keeping high the re-initiation eﬃ-
ciency, acting at the level of the termination event of the
uORF. Together with the stimulation of translation
obtained with the 222-323 construct, these results high-
light this region as an element that might act positively in
cis on the transcript and/or as a binding site for positive
trans-acting factors. Further work will address this issue in
light of the higher translation eﬃciency that has been
detected in primary neuronal cultures when compared
with other cell types, and considering the increase in
translation eﬃciency that can be obtained in astrocytes
upon activation with cytokines (38). Furthermore, even if
our data are not in favor of a speciﬁc model to explain the
striking diﬀerence in BACE1 translation between human
brain and pancreas, they keep open the two most notable
possibilities, i.e. the expression in pancreas of high levels
of a trans-acting factor (either a protein or a miRNA) that
inhibits translation of BACE1, and the existence in brain
of a regulator/mechanism that allows a partial skipping of
the uAUG block occurring in the other tissues. The
presence of multiple variants of the BACE1 transcript,
ascribed to alternative polyadenylation signals, may add
further complexity to this scenario.
ACKNOWLEDGEMENTS
M.M. was guest in Hentze’s laboratory for a year and
thanks the other members of the lab for useful discussions
and help. The work was carried out within the framework
of the Italian Ministry of Research Center of Excellence
in Physiopathology of Cell Diﬀerentiation. Financial
support was from the EU contract LSHM-CT-2003-
503330 (APOPIS) to D.Z., and the Italian Ministry of
Research (PRIN project 2006054051 to F.G. and FIRB
project RBLA03AF28_001 to D.Z.). Funding to pay the
Open Access publication charges for this article was
provided by the Italian Institute of Technology.
Conﬂict of interest statement. None declared.
REFERENCES
1. Hussain,I., Powell,D., Howlett,D.R., Tew,D.G., Meek,T.D.,
Chapman,C., Gloger,I.S., Murphy,K.E., Southan,C.D. et al. (1999)
Identiﬁcation of a novel aspartic protease (Asp 2) as beta-secretase.
Mol. Cell Neurosci., 14, 419–427.
2. Sinha,S., Anderson,J.P., Barbour,R., Basi,G.S., Caccavello,R.,
Davis,D., Doan,M., Dovey,H.F., Frigon,N. et al. (1999)
Puriﬁcation and cloning of amyloid precursor protein beta-secretase
from human brain. Nature, 402, 537–540.
3. Vassar,R., Bennett,B.D., Babu-Khan,S., Kahn,S., Mendiaz,E.A.,
Denis,P., Teplow,D.B., Ross,S., Amarante,P. et al. (1999) Beta-
secretase cleavage of Alzheimer’s amyloid precursor protein by the
transmembrane aspartic protease BACE. Science, 286, 735–741.
4. Yan,R., Bienkowski,M.J., Shuck,M.E., Miao,H., Tory,M.C.,
Pauley,A.M., Brashier,J.R., Stratman,N.C., Mathews,W.R. et al.
(1999) Membrane-anchored aspartyl protease with Alzheimer’s
disease beta-secretase activity. Nature, 402, 533–537.
5. Lin,X., Koelsch,G., Wu,S., Downs,D., Dashti,A. and Tang,J.
(2000) Human aspartic protease memapsin 2 cleaves the beta-
secretase site of beta-amyloid precursor protein. Proc. Natl Acad.
Sci. USA, 97, 1456–1460.
6. Hu,X., Hicks,C.W., He,W., Wong,P., Macklin,W.B., Trapp,B.D.
and Yan,R. (2006) Bace1 modulates myelination in the central
and peripheral nervous system. Nat. Neurosci., 9, 1520–1525.
7. Willem,M., Garratt,A.N., Novak,B., Citron,M., Kaufmann,S.,
Rittger,A., DeStrooper,B., Saftig,P., Birchmeier,C. et al. (2006)
Control of peripheral nerve myelination by the beta-secretase
BACE1. Science, 314, 664–666.
8. Li,Q. and Sudhof,T.C. (2004) Cleavage of amyloid-beta precursor
protein and amyloid-beta precursor-like protein by BACE 1.
J. Biol. Chem., 279, 10542–10550.
9. Pastorino,L., Ikin,A.F., Lamprianou,S., Vacaresse,N., Revelli,J.P.,
Platt,K., Paganetti,P., Mathews,P.M., Harroch,S. et al. (2004)
BACE (beta-secretase) modulates the processing of APLP2 in vivo.
Mol. Cell Neurosci., 25, 642–649.
10. Kitazume,S., Nakagawa,K., Oka,R., Tachida,Y., Ogawa,K.,
Luo,Y., Citron,M., Shitara,H., Taya,C. et al. (2005) In vivo cleavage
of alpha2,6-sialyltransferase by Alzheimer beta-secretase. J. Biol.
Chem., 280, 8589–8595.
11. Lichtenthaler,S.F., Dominguez,D.I., Westmeyer,G.G., Reiss,K.,
Haass,C., Saftig,P., De Strooper,B. and Seed,B. (2003) The cell
adhesion protein P-selectin glycoprotein ligand-1 is a substrate for
the aspartyl protease BACE1. J. Biol. Chem., 278, 48713–48719.
12. Wong,H.K., Sakurai,T., Oyama,F., Kaneko,K., Wada,K.,
Miyazaki,H., Kurosawa,M., De Strooper,B., Saftig,P. et al. (2005)
Beta subunits of voltage-gated sodium channels are novel substrates
of beta-site amyloid precursor protein-cleaving enzyme (BACE1)
and gamma-secretase. J. Biol. Chem., 280, 23009–23017.
13. von Arnim,C.A., Kinoshita,A., Peltan,I.D., Tangredi,M.M.,
Herl,L., Lee,B.M., Spoelgen,R., Hshieh,T.T., Ranganathan,S. et al.
(2005) The low density lipoprotein receptor-related protein (LRP) is
a novel beta-secretase (BACE1) substrate. J. Biol. Chem., 280,
17777–17785.
14. Cai,H., Wang,Y., McCarthy,D., Wen,H., Borchelt,D.R., Price,D.L.
and Wong,P.C. (2001) BACE1 is the major beta-secretase for
generation of Abeta peptides by neurons. Nat. Neurosci., 4,
233–234.
15. Luo,Y., Bolon,B., Kahn,S., Bennett,B.D., Babu-Khan,S., Denis,P.,
Fan,W., Kha,H., Zhang,J. et al. (2001) Mice deﬁcient in BACE1,
the Alzheimer’s beta-secretase, have normal phenotype and
abolished beta-amyloid generation. Nat. Neurosci., 4, 231–232.
16. Roberds,S.L., Anderson,J., Basi,G., Bienkowski,M.J.,
Branstetter,D.G., Chen,K.S., Freedman,S.B., Frigon,N.L.,
Games,D. et al. (2001) BACE knockout mice are healthy despite
lacking the primary beta-secretase activity in brain: implications for
Alzheimer’s disease therapeutics. Hum. Mol. Genet., 10, 1317–1324.
17. De Strooper,B. (2003) Aph-1, Pen-2, and nicastrin with presenilin
generate an active gamma-secretase complex. Neuron, 38, 9–12.
18. Haass,C. (2004) Take ﬁve—BACE and the gamma-secretase quartet
conduct Alzheimer’s amyloid beta-peptide generation. EMBO J.,
23, 483–488.
19. Hardy,J. and Selkoe,D.J. (2002) The amyloid hypothesis of
Alzheimer’s disease: progress and problems on the road to
therapeutics. Science, 297, 353–356.
20. Selkoe,D.J. (2004) Cell biology of protein misfolding: the examples
of Alzheimer’s and Parkinson’s diseases. Nat. Cell Biol., 6,
1054–1061.
21. Marcinkiewicz,M. and Seidah,N.G. (2000) Coordinated expression
of beta-amyloid precursor protein and the putative beta-secretase
BACE and alpha-secretase ADAM10 in mouse and human brain.
J. Neurochem., 75, 2133–2143.
22. Huse,J.T., Byant,D., Yang,Y., Pijak,D.S., D’Souza,I., Lah,J.J.,
Lee,V.M., Doms,R.W. and Cook,D.G. (2003) Endoproteolysis of
beta-secretase (beta-site amyloid precursor protein-cleaving enzyme)
within its catalytic domain. A potential mechanism for regulation.
J. Biol. Chem., 278, 17141–17149.
2984 Nucleic Acids Research, 2007, Vol. 35, No. 923. Laird,F.M., Cai,H., Savonenko,A.V., Farah,M.H., He,K.,
Melnikova,T., Wen,H., Chiang,H.C., Xu,G. et al. (2005) BACE1, a
major determinant of selective vulnerability of the brain to
amyloid-beta amyloidogenesis, is essential for cognitive, emotional,
and synaptic functions. J. Neurosci., 25, 11693–11709.
24. Velliquette,R.A., O’Connor,T. and Vassar,R. (2005) Energy
inhibition elevates beta-secretase levels and activity and is poten-
tially amyloidogenic in APP transgenic mice: possible early events in
Alzheimer’s disease pathogenesis. J. Neurosci., 25, 10874–10883.
25. Fukumoto,H., Cheung,B.S., Hyman,B.T. and Irizarry,M.C. (2002)
Beta-secretase protein and activity are increased in the neocortex in
Alzheimer disease. Arch. Neurol., 59, 1381–1389.
26. Holsinger,R.M.D., McLean,C.A., Beyreuther,K., Masters,C.L. and
Evin,G. (2002) Increased expression of the amyloid precursor
beta-secretase in Alzheimer’s disease. Ann. Neurol., 51, 783–786.
27. Tyler,S.J., Dawbarn,D., Wilcock,G.K. and Allen,S.J. (2002)
Alpha- and beta-secretase: profound changes in Alzheimer’s disease.
Biochem. Biophys. Res. Commun., 299, 373–376.
28. Yang,L.B., Lindholm,K., Yan,R., Citron,M., Xia,W., Yang,X.L.,
Beach,T., Sue,L., Wong,P. et al. (2003) Elevated beta-secretase
expression and enzymatic activity detected in sporadic Alzheimer
disease. Nat. Med., 9, 3–4.
29. Wilkie,G.S., Dickson,K.S. and Gray,N.K. (2003) Regulation of
mRNA translation by 50- and 30-UTR-binding factors. Trends
Biochem. Sci., 28, 182–188.
30. Gebauer,F. and Hentze,M.W. (2004) Molecular mechanisms of
translational control. Nat. Rev. Mol. Cell Biol., 5, 827–835.
31. Kozak,M. (2002) Pushing the limits of the scanning mechanism for
initiation of translation. Gene, 299, 1–34.
32. Kozak,M. (1999) Initiation of translation in prokaryotes and
eukaryotes. Gene, 234, 187–208.
33. Kozak,M. (2005) Regulation of translation via mRNA structure in
prokaryotes and eukaryotes. Gene, 361, 13–37.
34. Ryabova,L.A., Pooggin,M.M. and Hohn,T. (2002) Viral strategies
of translation initiation: ribosomal shunt and reinitiation. Prog.
Nucleic Acid Res. Mol. Biol., 72, 1–39.
35. Hellen,C.U. and Sarnow,P. (2001) Internal ribosome entry sites in
eukaryotic mRNA molecules. Genes Dev., 15, 1593–1612.
36. Stoneley,M. and Willis,AE. (2004) Cellular internal ribosome entry
segments: structures, trans-acting factors and regulation of gene
expression. Oncogene, 23, 3200–3207.
37. Baird,S.D., Turcotte,M., Korneluk,R.G. and Holcik,M. (2006)
Searching for IRES. RNA, 12, 1755–1785.
38. De Pietri Tonelli,D., Mihailovich,M., Di Cesare,A., Codazzi,F.,
Grohovaz,F. and Zacchetti,D. (2004) Translational regulation of
BACE-1 expression in neuronal and non-neuronal cells. Nucleic
Acids Res., 32, 1808–1817.
39. Lammich,S., Schobel,S., Zimmer,A.K., Lichtenthaler,S.F. and
Haass,C. (2004) Expression of the Alzheimer protease BACE1 is
suppressed via its 50-untranslated region. EMBO Rep., 5, 620–625.
40. Rogers,G.W. Jr, Edelman,G.M. and Mauro,V.P. (2004) Diﬀerential
utilization of upstream AUGs in the beta-secretase mRNA suggests
that a shunting mechanism regulates translation. Proc. Natl. Acad.
Sci. USA, 101, 2794–2799.
41. Iizuka,N., Najita,L., Franzusoﬀ,A. and Sarnow,P. (1994)
Cap-dependent and cap-independent translation by internal
initiation of mRNAs in cell extracts prepared from Saccharomyces
cerevisiae. Mol. Cell. Biol., 14, 7322–7330.
42. Thoma,C., Bergamini,G., Galy,B., Hundsdoerfer,P. and
Hentze,M.W. (2004) Enhancement of IRES-mediated translation of
the c-myc and BiP mRNAs by the poly(A) tail is independent of
intact eIF4G and PABP. Mol. Cell, 15, 925–935.
43. Bergamini,G., Preiss,T. and Hentze,M.W. (2000) Picornavirus
IRESes and the poly(A) tail jointly promote cap-independent
translation in a mammalian cell-free system. RNA, 6, 1781–1790.
44. Ge,Y.W., Maloney,B., Sambamurti,K. and Lahiri,D.K. (2004)
Functional characterization of the 50 ﬂanking region of the
BACE gene: identiﬁcation of a 91 bp fragment involved in
basal level of BACE promoter expression. FASEB J., 18,
1037–1039.
45. Zhou,W. and Song,W. (2006) Leaky scanning and reinitiation
regulate BACE1 gene expression. Mol. Cell Biol., 26, 3353–3364.
46. Kozak,M. (1997) Recognition of AUG and alternative initiator
codons is augmented by G in position þ4 but is not generally
aﬀected by the nucleotides in positions þ5 and þ6. EMBO J., 16,
2482–2492.
47. Sloan,J., Kinghorn,J.R. and Unkles,S.E. (1999) The two subunits
of human molybdopterin synthase: evidence for a bicistronic
messenger RNA with overlapping reading frames. Nucleic Acids
Res., 27, 854–858.
48. Stallmeyer,B., Drugeon,G., Reiss,J., Haenni,A.L. and Mendel,R.R.
(1999) Human molybdopterin synthase gene: identiﬁcation of a
bicistronic transcript with overlapping reading frames. Am. J. Hum.
Genet., 64, 698–705.
49. Sutter,G., Ohlmann,M. and Erﬂe,V. (1995) Non-replicating vaccinia
vector eﬃciently expresses bacteriophage T7 RNA polymerase.
FEBS Lett., 371, 9–12.
50. Kozak,M. (1989) Circumstances and mechanisms of inhibition of
translation by secondary structure in eucaryotic mRNAs. Mol. Cell.
Biol., 9, 5134–5142.
51. Kozak,M. (1986) Point mutations deﬁne a sequence ﬂanking the
AUG initiator codon that modulates translation by eukaryotic
ribosomes. Cell, 44, 283–292.
52. Gray,N.K. and Hentze,M.W. (1994) Regulation of protein synthesis
by mRNA structure. Mol. Biol. Rep., 19, 195–200.
53. Morris,D.R. and Geballe,A.P. (2000) Upstream open reading
frames as regulators of mRNA translation. Mol. Cell. Biol., 20,
8635–8642.
54. Kozak,M. (1987) Eﬀects of intercistronic length on the eﬃciency
of reinitiation by eucaryotic ribosomes. Mol. Cell. Biol., 7,
3438–3445.
55. Grant,C.M. and Hinnebusch,A.G. (1994) Eﬀect of sequence context
at stop codons on eﬃciency of reinitiation in GCN4 translational
control. Mol. Cell. Biol., 14, 606–618.
Nucleic Acids Research, 2007, Vol. 35, No. 9 2985